

Produktinformation



Forschungsprodukte & Biochemikalien
Zellkultur & Verbrauchsmaterial
Diagnostik & molekulare Diagnostik
Laborgeräte & Service

Weitere Information auf den folgenden Seiten! See the following pages for more information!



Lieferung & Zahlungsart siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien T. +43(0)1 489 3961-0 F. +43(0)1 489 3961-7 <u>mail@szabo-scandic.com</u> www.szabo-scandic.com

PRODUCT INFORMATION



Valbenazine

Item No. 26809

CAS Registry No.: Formal Name:	1025504-45-3 L-valine, (2R,3R,11bR)- 1,3,4,6,7,11b-hexahydro-9,10- dimethoxy-3-(2-methylpropyl)- 2H-benzo[a]quinolizin-2-yl ester	NH ₂
Synonym:	NBI-98854	
MF:	C ₂₄ H ₃₈ N ₂ O ₄	
FW:	418.6	
Purity:	≥98%	
Supplied as:	A crystalline solid	
Storage:	-20°C	`0´
Stability:	≥2 years	

Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Valbenazine is supplied as a crystalline solid. A stock solution may be made by dissolving the valbenazine in the solvent of choice. Valbenazine is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF), which should be purged with an inert gas. The solubility of valbenazine in these solvents is approximately 10, 25, and 30 mg/ml, respectively.

Valbenazine is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, valbenazine should first be dissolved in DMF and then diluted with the aqueous buffer of choice. Valbenazine has a solubility of approximately 0.33 mg/ml in a 1:2 solution of DMF:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

Valbenazine is an inhibitor of vesicular monoamine transporter 2 (VMAT2; K,s = 110 and 150 nM in rat striatum homogenates and human platelets, respectively).¹ It is selective for VMAT2 over a panel of 80 receptors, transporters, and ion channels, including the serotonin (5-HT) receptor subtypes 5-HT_{1A}, 5-HT_{2A}, and 5-HT_{2B} and dopamine D_1 and D_2 receptors. Valbenazine induces ptosis in rats, indicating norepinephrine depletion. Formulations containing valbenazine have been used in the treatment of tardive dyskinesia.

Reference

1. Grigoriadis, D.E., Smith, E., Hoare, S.R.J., et al. Pharmacologic characterization of valbenazine (NBI-98854) and its metabolites. J. Pharmacol. Exp. Ther. 361(3), 454-461 (2017).

WARNING THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

uyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 02/28/2019

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD ANN ARBOR, MI 48108 · USA PHONE: [800] 364-9897 [734] 971-3335 FAX: [734] 971-3640 CUSTSERV@CAYMANCHEM.COM WWW.CAYMANCHEM.COM